Commission Implementing Regulation (EU) 2016/125
of 29 January 2016
approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-types 2, 3, 11
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Whereas:
PHMB (1600; 1.8) has been evaluated for use in product-type 2, disinfectants and algaecides not intended for direct application to humans or animals, product-type 3, veterinary hygiene, and product-type 11, preservatives for liquid-cooling and processing systems, as defined in Annex V to Regulation (EU) No 528/2012.
France was designated as evaluating competent authority and submitted the assessment reports, together with its recommendations, on 8 October 2013 and 14 November 2013.
In accordance with Article 7(1)(b) of Delegated Regulation (EU) No 1062/2014, the opinions of the European Chemicals Agency were formulated on 17 June 2015 by the Biocidal Products Committee, having regard to the conclusions of the evaluating competent authority.
According to those opinions, biocidal products used for product-types 2, 3, and 11 and containing PHMB (1600; 1.8) may be expected to satisfy the requirements of Article 19(1)(b) of Regulation (EU) No 528/2012, provided that certain conditions concerning its use are complied with.
It is therefore appropriate to approve PHMB (1600; 1.8) for use in biocidal products for product-types 2, 3, and 11 subject to compliance with certain specifications and conditions.
PHMB (1600; 1.8) meets the conditions set out in point (d) of Article 10(1) of Regulation (EU) No 528/2012 and should therefore be considered a candidate for substitution.
Pursuant to Article 10(4) of Regulation (EU) No 528/2012, the approval of an active substance that is considered as a candidate for substitution should be for a period not exceeding 7 years.
Since PHMB (1600; 1.8) meets the criteria for being very persistent (vP) according to Annex XIII to Regulation (EC) No 1907/2006, treated articles treated with or incorporating PHMB (1600; 1.8) should be appropriately labelled when placed on the market.
A reasonable period should be allowed to elapse before an active substance is approved, in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,
HAS ADOPTED THIS REGULATION: